Allergic Reactions to COVID-19-Vaccines - What ENT-Doctors should know Part 1: General Aspects of Allergies to Vaccines, immunological Basis of Allergies to Vaccines, Immune Mechanisms of allergic and pseudoallergic Reactions Part 2: : Characteristics of the mRNA-Vaccines BNT162b2 and mRNA-1273 for Prophylaxis of COVID-19 and associated Immune Phenomena Part 3: Practical Aspects of the Prophylaxis, Diagnosis and Therapy of Allergies to COVID-19-Vaccines

With BNT162b2 (approved in the EC on 27(th) of December 2020) and mRNA-1273 (approved in the EC on 6(th) of January 2021) for the first time ever two RNA-vaccines received conditional approval within the EC in order to effectively combat the SARS-COV2 pandemic The emergence of sporadic cases of anaphylaxis following vaccination with these new compounds and the identification of PEGs (polyethylenglycols) as potential, widely used but yet usually unknown culprits have led to uncertainty among treating physicians and patients The aim of this article series is to summarize current available pathophysiological and clinical information (part 1), to describe the characteristics of the vaccines (part 2) and to provide practical solutions for diagnosis and treatment of potential allergy against mRNACovid19 vaccines